Slide 1: Revolutionizing indoor health through light
Revolutionizing indoor health through light TSX-V: UVC OTCQB: FUVCF Investor presentation
Slide 2: Important disclosures
TSX-V: UVC LEGAL NOTICE Important disclosures. FORWARD-LOOKING INFORMATION INDUSTRY & MARKET DATA This presentation contains "forward-looking information" within the meaning of applicable Canadian securities laws and "forward-looking statements" within the meaning of the United States Private Securi
Slide 3: Indoor spaces are making people sick, and the world is finally demanding a solution
TSX-V: UVC THE PROBLEM Indoor spaces are making people sick, and the world is finally demanding a solution. THE COST OF INACTION WHY NOW 2024-26 INFLECTION FOUR CONVERGING FORCES 10M+ 01 Indoor air is a health crisis HAIs kill more people than car accidents. Indoor transmission drives pandemic econo
Slide 4: Two pillars of innovation
TSX-V: UVC OUR TECHNOLOGY PLATFORM Two pillars of innovation. Comprehensive lighting solutions that save energy and protect health through our mastery of the light spectrum. HEALTH CANADA REGISTERED 19+ PATENTS 100% MADE IN CANADA UPPER-ROOM GUV 99.7% PATHOGEN KILL FAR-UVC PRE-COMMERCIAL / Q1 2027 D
Slide 5: The science of UVC is proven. The problem, until now, was human safety
TSX-V: UVC THE TECHNOLOGY The science of UVC is proven. The problem, until now, was human safety. FOUNDATION SANILUME / 254 NM SANILUX / 216 NM UVC destroys pathogens, Upper-room germicidal UV. Far-UVC, human-safe physically, not chemically. disinfection. Mounted above head-height so occupants never
Slide 6: Our product family
TSX-V: UVC PRODUCT PORTFOLIO Our product family. LED LIGHTING REVENUE PRODUCING GERMICIDAL UV ACTIVE REVENUE FAR-UVC LAUNCHING SOON ECOWing SaniLume SaniLux Diffused LED lighting. Industry-leading commercial LED retrofit; Upper-room Germicidal UV. The only Health Canada-registered Far-UVC at 216 nm,
Slide 7: The most effective upper-room germicidal UV device
TSX-V: UVC ACTIVE REVENUE 254 NM HEALTH CANADA REGISTERED The most effective upper-room germicidal UV device in the market. SANILUME Independently validated at the University of Leeds aerobiology chamber, 2022. 201-1,994 99.7% 750 ft² EQUIV. AIR ELIMINATION RATE COVERAGE CHANGES / HR CDC ventilation
Slide 8: Independent validation: University of Leeds
TSX-V: UVC INDEPENDENT VALIDATION: UNIVERSITY OF LEEDS The most powerful upper-room GUV device on the market. “ The best performing UV device that has been tested in the aerobiology chamber at the University of Leeds to date. DR. LOUISE FLETCHER SCHOOL OF CIVIL ENGINEERING, UNIVERSITY OF LEEDS · AER
Slide 9: Validated economics. Mandatory demand.
TSX-V: UVC COMMERCIAL CASE Validated economics. Mandatory demand. From the CHAIR national economic model, to the unit economics of a tertiary deployment, to the bottom-up North American hospital SAM. CHAIR MODEL HOSPITAL SECTOR TERTIARY DEPLOYMENT Q2 2026 PHASE 1 SAM N. AMERICAN HOSPITALS The nation
Slide 10: SaniLux: A fundamental shift, not an increment
TSX-V: UVC SANILUX C O M I N G S O O N FAR-UVC | 216 NM A fundamental shift , not an increment. Proprietary 216 nm solid-state Far-UVC. IP owned outright by Illumisoft, not licensed excimer. 70× MORE POWERFUL <1min* KILL TIME Human-safe at 216 nm; cannot penetrate skin or eyes. Unlocks continuous di
Slide 11: SaniLux vs. conventional Far-UVC
TSX-V: UVC TECHNOLOGY ADVANTAGE SaniLux vs. conventional Far-UVC, every competitor licenses excimer from one Japanese supplier. R-Zero raised $170M USD and still cannot serve aviation, transit or commercial, hard excimer power limits. SaniLux is solid-state, Watt- range, owned outright. METRIC EXCIM
Slide 12: Why Far-UVC is the future of indoor air
TSX-V: UVC INDUSTRY VALIDATION / BLUEPRINT BIOSECURITY Why Far-UVC is the future of indoor air. Independent assessment by Blueprint Biosecurity, the leading nonprofit advancing pandemic-preparedness infrastructure. Their 266-page Blueprint for Far-UVC report (2025) is the definitive technical and po
Slide 13: ECOWing 60-75% less energy
TSX-V: UVC REVENUE PRODUCING DIFFUSED LED ECOWing 60-75% less energy. 167 lm/W of DLC-listed efficiency, engineered and manufactured in Ottawa. The beachhead that opens every door. 34/50 17 40-55% #1 DLC RANKING TOP DLC FIXTURES PATENTS GROSS MARGIN ECOWING DIFFUSED LED Every ECOWing install is a wa
Slide 14: $248B global market / bottom-up path to $100M revenue
TSX-V: UVC MARKET OPPORTUNITY $248B global market / bottom-up path to $100M revenue. INFECTION CONTROL 2024 BY 2034 CAGR UV PENETRATION N. AMERICA SHARE $248B $473B 6.7% 5→30% 40-49% SANILUME / GUV TODAY SANILUX / FAR-UVC UNPRICED OPTION ECOWING / LED ESTABLISHED REVENUE $9.7B Hospital SAM / 230K ×
Slide 15: Government, healthcare, real-estate, already on board
TSX-V: UVC TRACTION | TRUSTED BY INDUSTRY LEADERS Government, healthcare, real-estate, already on board. In partnership with Health Canada and the NRC to help establish Workplace 3.0 standards for Federal buildings. REGULATORY R&D PARTNER REAL ESTATE REAL ESTATE REAL ESTATE FEDERAL HOSPITAL PILOT ST
Slide 16: Canada first. The world follows the standard.
TSX-V: UVC GO-TO-MARKET & SCALE Canada first. The world follows the standard. PHASE 01 / NOW ACTIVE PHASE 02 / 12-24 MO QUEUED PHASE 03 / 24+ MO SCALE Dominate Canada US & International SaniLux at scale CSA mandate delivers immediate SaniLume Health Canada registration is the proof point Far-UVC unl
Slide 17: Backed by global visionaries
TSX-V: UVC MAJOR STRATEGIC INVESTMENT Backed by global visionaries. Chris Anderson (Founder of TED) and Rob Reid (Creator of Rhapsody) have made a significant ownership commitment through their joint venture, Resilience Reserve LLC. OWNERSHIP STAKE 19.43% Chris Anderson & Rob Reid / Resilience Reser
Slide 18: Ottawa-built. Engineered across every wavelength that matters.
TSX-V: UVC ABOUT ILLUMISOFT Ottawa-built. Engineered across every wavelength that matters. A Canadian photonics company with two commercial product lines, one breakthrough R&D program, and a leadership team drawn from public markets, semiconductor physics, and global-health venture capital. FOUNDED
Slide 19: Capital structure
TSX-V: UVC CAPITAL STRUCTURE PRO-FORMA SHARES OUTSTANDING USE OF PROCEEDS Capitalization at listing. Capital deployment. Claranova shares to shareholders 22,261,805 Manufacturing & inventory scale ~35% Gstaad post-consolidation (5:1) 1,881,667 Sales & channel expansion (CA / US) ~25% Concurrent fina
Slide 20: Six reasons. Why illumisoft.
TSX-V: UVC INVESTMENT THESIS Six reasons. Why illumisoft. TODAY MANDATORY VALIDATED 100× UNPRICED $200B+ Mandatory market, today Validated performance SaniLux / $200B+ option Canadian CSA Z317.12:25 mandates UV. SaniLume is Leeds: 1,994 eACH vs. 0.003-17 for all other 70× more powerful than excimer.
Slide 21: Proven technology. Mandatory market. Generational entry point.
Proven technology. Mandatory market. Generational entry point. WEB CONTACT REGISTERED TICKER illumisoft.com info@illumisoft.com Ottawa, Canada TSX-V: UVC OTCQB: FUVCF